Rare Diseases: Drug Discovery and Informatics Resource
暂无分享,去创建一个
[1] W. Hauswirth,et al. Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency , 2010, Gene Therapy.
[2] O. Goker-Alpan,et al. Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease , 2016, PloS one.
[3] R. Tagliaferri,et al. Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.
[4] G. Stamatoyannopoulos,et al. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. , 2015, Blood.
[5] Á. Atallah,et al. Enzyme replacement therapy for Fabry disease , 2007 .
[6] Zheng Li,et al. Drug-Disease Association and Drug-Repositioning Predictions in Complex Diseases Using Causal Inference-Probabilistic Matrix Factorization , 2014, J. Chem. Inf. Model..
[7] Cheng Zhu,et al. Drug repositioning for orphan diseases , 2011, Briefings Bioinform..
[8] Giovanni Colonna,et al. Modeling of the Bacterial Mechanism of Methicillin-Resistance by a Systems Biology Approach , 2009, PloS one.
[9] Dongqing Wei,et al. The α7 nAChR selective agonists as drug candidates for Alzheimer's disease. , 2015, Advances in experimental medicine and biology.
[10] R. Bazan,et al. Enzyme replacement therapy for Anderson-Fabry disease. , 2016, The Cochrane database of systematic reviews.
[11] A. J. Roman,et al. Improvement and decline in vision with gene therapy in childhood blindness. , 2015, The New England journal of medicine.
[12] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[13] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[14] Stephen T. C. Wong,et al. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. , 2014, Drug discovery today.
[15] Brian K. Shoichet,et al. The incorporation of protein flexibility and conformational energy penalties in docking screens to improve ligand discovery , 2014, Nature chemistry.
[16] S. Lai,et al. Targeted high-efficiency, homogeneous myocardial gene transfer. , 2007, Journal of molecular and cellular cardiology.
[17] P. Fisher,et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.
[18] Irena Melnikova,et al. Rare diseases and orphan drugs , 2012, Nature Reviews Drug Discovery.
[19] H Moghadam,et al. Scoring multiple features to predict drug disease associations using information fusion and aggregation , 2016, SAR and QSAR in environmental research.
[20] P. Song,et al. Innovative measures to combat rare diseases in China: The national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research. , 2017, Intractable & rare diseases research.
[21] P. Aloy,et al. Unveiling the role of network and systems biology in drug discovery. , 2010, Trends in pharmacological sciences.
[22] Steven J. M. Jones,et al. FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project. , 2014, American journal of human genetics.
[23] Yi Li,et al. Multi-algorithm and multi-model based drug target prediction and web server , 2014, Acta Pharmacologica Sinica.
[24] O. Gabrielli,et al. Update on treatment of lysosomal storage diseases. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[25] L. Cardon,et al. Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.
[26] C. Hollak,et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients , 2016, Orphanet Journal of Rare Diseases.
[27] Y.Z. Chen,et al. Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.
[28] Kui Xu,et al. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases , 2011, Briefings Bioinform..
[29] Jin Han Lo,et al. Elosulfase alfa: First Global Approval , 2014, Drugs.
[30] A. Amalfitano,et al. Recent advances in gene therapy for lysosomal storage disorders , 2015, The application of clinical genetics.
[31] Chuang Liu,et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..
[32] J. Chou,et al. Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice. , 2009, Journal of hepatology.
[33] Jinxiang Han,et al. Defining rare diseases in China. , 2017, Intractable & rare diseases research.
[34] Youngmi Yoon,et al. A Network-Based Classification Model for Deriving Novel Drug-Disease Associations and Assessing Their Molecular Actions , 2014, PloS one.
[35] D. di Bernardo,et al. Identification of small molecules enhancing autophagic function from drug network analysis. , 2010, Autophagy.
[36] G. Nagel,et al. Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia , 2013, BMC Neurology.
[37] K. Tsuda,et al. Mining Significant Substructure Pairs for Interpreting Polypharmacology in Drug-Target Network , 2011, PloS one.
[38] François Schiettecatte,et al. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..
[39] A. Vergara,et al. Rare Diseases: A Current View , 2017 .
[40] Xin Yao,et al. Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network , 2011, BMC Systems Biology.
[41] Jianfeng Pei,et al. Systems biology brings new dimensions for structure-based drug design. , 2014, Journal of the American Chemical Society.
[42] S. Ortolano,et al. Treatment of lysosomal storage diseases: recent patents and future strategies. , 2014, Recent patents on endocrine, metabolic & immune drug discovery.
[43] F. Mavilio,et al. Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry , 2017, Gene Therapy.
[44] Igor Goryanin,et al. Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[45] Xing-Ming Zhao,et al. Drug-Domain Interaction Networks in Myocardial Infarction , 2013, IEEE Transactions on NanoBioscience.
[46] G. Vriend,et al. A text-mining analysis of the human phenome , 2006, European Journal of Human Genetics.
[47] Jean Bennett,et al. Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[48] Asher Mullard. Gene therapies advance towards finish line , 2011, Nature Reviews Drug Discovery.
[49] E. Bender. Gene therapy: Industrial strength , 2016, Nature.
[50] Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis. , 2016, The oncologist.
[51] Dongqing Wei,et al. Exploring the Ligand-Protein Networks in Traditional Chinese Medicine: Current Databases, Methods and Applications , 2014, Advances in experimental medicine and biology.
[52] Peng Gang Sun,et al. The human Drug-Disease-Gene Network , 2015, Inf. Sci..
[53] M. Andreani,et al. Allogeneic cellular gene therapy in hemoglobinopathies—evaluation of hematopoietic SCT in sickle cell anemia , 2012, Bone Marrow Transplantation.
[54] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[55] Manuel Corpas,et al. DECIPHER: web-based, community resource for clinical interpretation of rare variants in developmental disorders. , 2012, Human molecular genetics.
[56] Gang Feng,et al. Disease Ontology: a backbone for disease semantic integration , 2011, Nucleic Acids Res..
[57] P. Robinson,et al. The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. , 2008, American journal of human genetics.
[58] Thomas C. Wiegers,et al. A CTD–Pfizer collaboration: manual curation of 88 000 scientific articles text mined for drug–disease and drug–phenotype interactions , 2013, Database J. Biol. Databases Curation.
[59] R. Dwek,et al. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. , 2005, Glycobiology.
[60] Jean Bennett,et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial , 2016, The Lancet.
[61] Francesco Iorio,et al. Identification of small molecules enhancing autophagic function from drug network analysis , 2010 .
[62] P. Elliott,et al. The heart in Anderson-Fabry disease and other lysosomal storage disorders , 2007, Heart.
[63] Michael J. Keiser,et al. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. , 2010, Journal of medicinal chemistry.
[64] R. Hopkin,et al. The management and treatment of children with Fabry disease: A United States-based perspective. , 2016, Molecular genetics and metabolism.
[65] R. Solé,et al. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.
[66] A. Olowoyeye,et al. Gene therapy for sickle cell disease. , 2010, The Cochrane database of systematic reviews.
[67] S. Nagueh. Anderson-Fabry Disease and Other Lysosomal Storage Disorders , 2014, Circulation.
[68] M. Whyte. Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[69] Luonan Chen,et al. Network-based drug repositioning. , 2013, Molecular bioSystems.
[70] M. Cubellis,et al. Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones , 2013, Orphanet Journal of Rare Diseases.
[71] Armando Blanco,et al. DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data , 2015, Artif. Intell. Medicine.
[72] S. Maiella,et al. Orphanet et son réseau : où trouver une information validée sur les maladies rares , 2013 .
[73] Xiaomin Luo,et al. TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..
[74] Luigi Naldini,et al. Gene therapy returns to centre stage , 2015, Nature.
[75] Caterina Bissantz,et al. Conformational Changes of G Protein‐Coupled Receptors During Their Activation by Agonist Binding , 2003, Journal of receptor and signal transduction research.
[76] Xiaofeng Liu,et al. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method , 2013, Bioinform..
[77] M. Murray,et al. Lysosomal Acid Lipase Deficiency , 2020, Contemporary Cardiology.
[78] Luonan Chen,et al. Drug repositioning framework by incorporating functional information. , 2013, IET systems biology.
[79] Y. Z. Chen,et al. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.
[80] A. Cheng,et al. Challenges in orphan drug development and regulatory policy in China , 2017, Orphanet Journal of Rare Diseases.
[81] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[82] Xing-Ming Zhao,et al. Predicting drug targets based on protein domains. , 2012, Molecular bioSystems.
[83] R. Moxley,et al. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). , 2012, Contemporary clinical trials.
[84] Alessandro Aiuti,et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.
[85] Maria Vittoria Cubellis,et al. Drug repositioning can accelerate discovery of pharmacological chaperones , 2015, Orphanet Journal of Rare Diseases.
[86] Charles H Jones,et al. Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. , 2016, Trends in biotechnology.
[87] Yi Pan,et al. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm , 2016, Bioinform..
[88] F. Dhombres,et al. Representation of rare diseases in health information systems: The orphanet approach to serve a wide range of end users , 2012, Human mutation.
[89] A. Simeonov,et al. Drug discovery and development for rare genetic disorders , 2017, American journal of medical genetics. Part A.
[90] Peng Jiang,et al. Molecular networks for the study of TCM Pharmacology , 2010, Briefings Bioinform..
[91] L. Meijer,et al. Inverse in silico screening for identification of kinase inhibitor targets. , 2007, Chemistry & biology.
[92] J. Lamerdin,et al. Identifying off-target effects and hidden phenotypes of drugs in human cells , 2006, Nature chemical biology.
[93] Michael Q. Zhang,et al. Network-based global inference of human disease genes , 2008, Molecular systems biology.
[94] C. Hollak,et al. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. , 2015, Best practice & research. Clinical endocrinology & metabolism.
[95] K. Bushby,et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases , 2013, Orphanet Journal of Rare Diseases.
[96] Michael Brudno,et al. PhenomeCentral: A Portal for Phenotypic and Genotypic Matchmaking of Patients with Rare Genetic Diseases , 2015, Human mutation.
[97] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[98] A. Markham. Migalastat: First Global Approval , 2016, Drugs.
[99] Holger Fröhlich,et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance , 2009, BMC Systems Biology.
[100] François Schiettecatte,et al. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..
[101] Ralf Hofestädt,et al. RAMEDIS: a comprehensive information system for variations and corresponding phenotypes of rare metabolic diseases , 2010, Human mutation.
[102] A. Chiang,et al. Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.
[103] Naruemon Pratanwanich,et al. Pathway-based Bayesian inference of drug-disease interactions. , 2014, Molecular bioSystems.
[104] M. Michaelides,et al. Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 , 2016, Gene Therapy.
[105] Ivan Molineris,et al. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs) , 2013, BMC Bioinformatics.
[106] P. van Damme,et al. Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR) , 2014, Acta Neurologica Belgica.
[107] G. Whitesides,et al. Combinatorial computational method gives new picomolar ligands for a known enzyme , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[108] Kai Huang,et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..
[109] D. Lockhart,et al. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.
[110] P. Hajduk,et al. Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. , 2010, Current opinion in chemical biology.
[111] Maria F. Sassano,et al. A Pharmacological Organization of G Protein-coupled Receptors , 2012, Nature Methods.
[112] Lin He,et al. Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study , 2011, PLoS Comput. Biol..
[113] R. Iyengar,et al. Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.
[114] Yaffa R Rubinstein,et al. NIH/NCATS/GRDR® Common Data Elements: A leading force for standardized data collection. , 2015, Contemporary clinical trials.
[115] Khader Shameer,et al. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. , 2015, Current topics in medicinal chemistry.
[116] E. Dmitrovsky,et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.